Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Xiaoguang Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3865-7537; OpenAlex author ID A5100379580. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. Research progress of plant-derived chemical compounds for overcoming pancreatic cancer drug resistance. Last author DOI 10.3748/wjg.v32.i9.115131↗
  2. Plasma lipid levels are associated with the CD8+ T-cell infiltration and prognosis of patients with pancreatic cancer. Co-author DOI 10.1002/cam4.6080↗
  3. LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer. First author DOI 10.3389/fonc.2022.1004212↗
  4. The expression and clinical prognostic value of protein phosphatase 1 catalytic subunit beta in pancreatic cancer. Co-author DOI 10.1080/21655979.2021.1934243↗
  5. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. Co-author DOI 10.3892/etm.2021.10574↗
  6. AMP‑activated protein kinase family member 5 is an independent prognostic indicator of pancreatic adenocarcinoma: A study based on The Cancer Genome Atlas. Last author DOI 10.3892/mmr.2020.11504↗
  7. CXCL5 expression in tumor tissues is associated with poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3892/ol.2020.12120↗
  8. Inflammatory and Senescent Phenotype of Pancreatic Stellate Cells Induced by Sqstm1 Downregulation Facilitates Pancreatic Cancer Progression. Co-author DOI 10.7150/ijbs.27825↗
  9. Detection of K-ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study. Co-author DOI 10.3892/etm.2017.5368↗
  10. Novel three‑lncRNA signature predicts survival in patients with pancreatic cancer. Co-author DOI 10.3892/or.2018.6761↗
  11. [Alpha-fetoprotein-producing pancreatic cancer: a case report]. First author DOI 10.3760/cma.j.issn.0253-3766.2017.06.015↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhengxiang Zhong · 8 shared papers, 2017–2023 · strength 1.02
  2. Lingyu Hu · 3 shared papers, 2021–2026 · strength 0.54
  3. Fei Chen · 4 shared papers, 2018–2022 · strength 0.52
  4. Zhengwei Song · 4 shared papers, 2018–2022 · strength 0.49
  5. Haokai Xu · 3 shared papers, 2020–2021 · strength 0.39
  6. Bin Yan Wu · 2 shared papers, 2020–2021 · strength 0.27
  7. Jia-Qi Yu · 1 shared paper, 2026 · strength 0.26
  8. Wei Chen · 2 shared papers, 2020–2021 · strength 0.25
  9. Bin Wu · 1 shared paper, 2023 · strength 0.20
  10. Xujian Chen · 1 shared paper, 2023 · strength 0.20
  11. Xiaorong Liu · 1 shared paper, 2022 · strength 0.16
  12. Peter Wang · 1 shared paper, 2022 · strength 0.16
  13. Jing Wang · 1 shared paper, 2020 · strength 0.13
  14. Yiyu Shen · 1 shared paper, 2020 · strength 0.13
  15. Tianpeng Wang · 1 shared paper, 2017 · strength 0.12
  16. Lifeng Qi · 1 shared paper, 2018 · strength 0.11
  17. Wei Chen · 1 shared paper, 2019 · strength 0.10
  18. Chuxiao Shao · 1 shared paper, 2019 · strength 0.10
  19. Xiangdong Cheng · 1 shared paper, 2019 · strength 0.10
  20. Fei Chen · 1 shared paper, 2018 · strength 0.08
  21. Bin Wu · 1 shared paper, 2018 · strength 0.08
  22. Jun Gao · 1 shared paper, 2018 · strength 0.08
  23. Kaixuan Wang · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.